Mindray Medical International
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Mindray Medical International's revenues will increase 15.1% and EPS will increase 15.9%.
The average estimate for revenue is $304.1 million. On the bottom line, the average EPS estimate is $0.51.
Last quarter, Mindray Medical International booked revenue of $257.1 million. GAAP reported sales were 18% higher than the prior-year quarter's $218.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.42. GAAP EPS of $0.30 for Q3 were 3.2% lower than the prior-year quarter's $0.31 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 56.0%, 110 basis points better than the prior-year quarter. Operating margin was 15.2%, 250 basis points worse than the prior-year quarter. Net margin was 13.9%, 320 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $1.06 billion. The average EPS estimate is $1.77.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 1,347 members out of 1,382 rating the stock outperform, and 35 members rating it underperform. Among 285 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 273 give Mindray Medical International a green thumbs-up, and 12 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Mindray Medical International is outperform, with an average price target of $35.51.
Is Mindray Medical International the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Mindray Medical International to My Watchlist.